GrayMatters Health (GMH) is a health technology company focused on developing and marketing innovative solutions for treating mental disorders. Their approach is based on the world's first digital brain biomarkers, aiming to provide more precise and effective therapeutic interventions. The company has received recognition, including the 2023 USA Prix Galien Best Startup award, and is actively deploying its FDA-cleared Prism for PTSD.